 NEW YORK, July 19, 2021 PRNewswire -- Immunic, Inc. the Company Nasdaq: IMUX, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the closing of an underwritten public offering of 4,500,000 shares of its common stock at a public offering price of 10.00 per share. The Company received total proceeds from the offering, before deducting the underwriting discounts and other offering expenses, of 45.0 million. 